These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9236854)

  • 1. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
    Henry SP; Monteith D; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):395-408. PubMed ID: 9236855
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligodeoxynucleotides as clinical therapeutic agents.
    Tonkinson JL; Stein CA
    Cancer Invest; 1996; 14(1):54-65. PubMed ID: 8597889
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
    Nieborowska-Skórska M; Białek AP; Nicolaides NC; Iozzo RV; Kawalec M; Calabretta B; Kawiak J; Marlicz K; Skórski T
    Folia Histochem Cytobiol; 1996; 34(2):69-73. PubMed ID: 8875213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
    Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
    Agrawal S
    Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.
    Wagner RW; Matteucci MD; Lewis JG; Gutierrez AJ; Moulds C; Froehler BC
    Science; 1993 Jun; 260(5113):1510-3. PubMed ID: 7684856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
    Geary RS; Yu RZ; Levin AA
    Curr Opin Investig Drugs; 2001 Apr; 2(4):562-73. PubMed ID: 11566019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
    Henry SP; Geary RS; Yu R; Levin AA
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
    Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
    Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense therapeutics.
    Agrawal S; Zhao Q
    Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
    Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.